

Molecular recognition of aortic valve stenosis and regurgitation

P. URBAN¹, M. RABAJDOVÁ¹, I. ŠPAKOVÁ¹, F. SABOL², H. MIČKOVÁ³,
K. LAKATOSOVÁ¹, M. ZAVACKÁ⁴

¹Department of Medical and Clinical Biochemistry, Pavol Jozef Šafárik University in Košice, Faculty of Medicine, Košice, Slovak Republic

²Department of Cardiovascular Surgery, Pavol Jozef Šafárik University in Košice and VUSCH, Faculty of Medicine, Košice, Slovak Republic

³Department of Medical Biology, Pavol Jozef Šafárik University in Košice, Faculty of Medicine, Košice, Slovak Republic

⁴Department of Vascular Surgery, Pavol Jozef Šafárik University in Košice and VUSCH, Faculty of Medicine, Košice, Slovak Republic

Abstract. – OBJECTIVE: Aortic valve stenosis (AS) presents a disease during which there are changes of the aortic valve structure that modify the blood structure of patients. The aim of this study was to improve the effectiveness of differential diagnostics of aortic stenosis and aortic regurgitation using molecular techniques on both mRNA (RT-PCR) and protein (biochip protein).

PATIENTS AND METHODS: An experimental group (n = 58) consisting of patients with aortic valve stenosis (n = 26) and aortic regurgitation (AR, n = 32) was compared with a control group (n = 35). Both blood serum and valve tissue samples were used for the determination of gene expression specific genes related to inflammatory response (CRP, IL6, IL2R, IL6R, TNFR1, and 2) as well as genes and proteins involved in remodeling of the extracellular matrix (MMP9, TIMP, Emilin-1).

RESULTS: We found that hsCRP and IL6 plasma levels of patients with AS were higher than both controls and patients with AR (mean 5.6 ng/ml). The differences between AS and AR were detected only in mRNA levels of MMP9 and TIMP where increased levels characteristic for AS were found (about 74%, $p < 0.01$ and 87%, $p < 0.001$ higher than AR).

CONCLUSIONS: The achieved results could contribute to the improvement of early diagnosis of selected cardiovascular disease in the future and improve the quality of patient's life.

Key Words:

Aortic valve stenosis, Blood serum, Aortic tissue, Gene expression, RT-PCR.

cific by progressive aortic valve narrowing and secondary hypertrophy². The earliest pathophysiological stages are characterized by endothelial damage, lipid deposition, and inflammation. All that results in leaflet stiffening reduced separation and valve narrowing³. The biochemical mechanisms, such as inflammation, lipid infiltration, extracellular matrix remodeling, and finally calcification in the wall of the aortic valve are activated during the aortic valve stenosis formation and progression⁴.

The inflammatory process begins with disruption of valve endothelium, followed by infiltration of inflammatory cells, mainly macrophages and T-lymphocytes⁵. Apolipoproteins increase oxidized low density lipoproteins (LDL) level during the inflammatory process⁶. C-reactive protein (CRP), one of the basic inflammatory markers, occurs in the extracellular matrix of the damaged aortic valve⁷. Tumor necrosis factor- α (TNF- α) and interleukin-6 (IL6) have also been found in the extracellular matrix of the aortic valve, predominantly in areas of leukocytes and macrophage infiltration. This pro-inflammatory cytokine is secreted by activated macrophages during a bacterial infection and the extracellular matrix remodeling⁸. It is responsible for immune regulation, inflammation, and tissue remodeling⁹.

The extracellular matrix remodeling of the aortic valve is also caused by the increased production of the matrix metalloproteinases (mainly MMP-2 and MMP9). These specific enzymes degrade collagen and elastin fibers¹⁰.

The degradation of MMPs by endogenous tissue inhibitors of MMPs (TIMPs) decreases the

Introduction

Aortic valve stenosis (AS) is the most common form of adult heart valve disease¹, that is spe-

proteolysis of the extracellular matrix¹¹. The imbalance between activities of MMPs and TIMPs leads to the destruction of the tissue structure. Biochemical processes then initiate inflammation and the formation of diseases on molecular level, such as abdominal aortic aneurysm, hypertension, valvular diseases¹².

Aortic regurgitation (AR) is characterized by regurgitation of blood from the aorta to the left ventricle (LV) during diastole. It is attributable to diverse congenital and acquired abnormalities of the aortic valve or the wall of the aortic root¹³. Acute severe AR may be difficult to recognize clinically and is often erroneously diagnosed as another acute condition, such as sepsis, pneumonia, or nonvalvular heart disease¹⁴.

AS and AR are a heterogeneous diseases with a complex pathophysiology involving the aortic valve and interconnected cardiac structures. For careful clinical assessment of AS or AR occurrence, echocardiography that is currently used has functional limitations for stratification of risk patients with asymptomatic progression¹⁵.

The aim of this study was to improve the effectiveness of differential diagnostics of AS and AR using molecular techniques (RT-PCR) and biochip protein analysis. A prompt and accurate diagnosis of acute AS or AR is of great importance, as urgent or emergent aortic valve surgery could be life-saving.

Patients and Methods

Experimental Design

The control group consists of healthy blood donors (n = 35), whose blood was collected by the National Blood Transfusion Service in Košice. The experimental group (n = 58) consists of patients with aortic valve stenosis (n = 26) and

aortic regurgitation (n = 32), (with clinically confirmed diagnosis), provided by the Department of Cardiovascular Surgery UPJS LF and VÚSCH, a.s. in Košice. The demographic and clinical characteristics of subjects are given in Table I.

The members of both studied groups (healthy subjects and patients) were informed by their doctor about the aim of our experimental study. All subjects signed an informed consent. The ethical consent for this study was given by the Institutional Committee on Human Research, and was approved by the Ethical Committee of the East Slovak Institute of Cardio-Vascular diseases (VÚSCH) from the date 3 June 2013. The ethical consent is compliant with the Ethical Standards on Human Experimentation and with the Declaration of Helsinki.

Blood and Tissue Collecting

The peripheral venous blood samples from the control group (6 ml), collected during the blood donation, and the experimental group of patients (6 ml), taken before the surgical intervention, were collected into the BD Vacutainer K₂EDTA and BD blood clot tubes (Terumo Deutschland GmbH, Eschborn, Germany). Patients in the experimental group with the presence of comorbidities, like atherosclerosis or ischemic heart disease, were excluded from the study. The whole blood was immediately used for mRNA isolation. Simultaneously, the blood samples intended for protein isolation were centrifuged for 3 minutes at 3500 rpm (BOECO, Hamburg, Germany) for blood serum separation.

The healthy aortic valve tissue material (control group) was taken from individuals after traumatic death during autopsy. All necrotic samples were collected 2 to 5 hours after confirmation of time of death. The samples were collected in cooperation with the Department of Forensic

Table I. The demographic and clinical characteristics of experimental and control group.

	Control	AS	AR
Number of patients	35	26	32
Gender (F/M, female %)	20/15 (57%)	4/22 (18.2%)	6/26 (23.1%)
Age (years)	45 ± 9.6	55.6 ± 13.1	54.6 ± 11.7
Aorta diameter (mm)	–	4.7 ± 1.1	5.36 ± 0.61
BAV/TAV	–	14/12 (53.8%)	23/9 (71.9%)
Hypertension	5/35 (14%)	16/26 (61.5%)	20/32 (62.5%)
Diabetes mellitus	0	2/26 (7.6%)	1/32 (3.1%)
Current smokers	9/35 (26%)	10/26 (38.5%)	12/32 (37.5%)
BMI	26.4 ± 4.2	29.7 ± 5.9	27.9 ± 4.47
Weight (kg)	76.9 ± 15.2	87 ± 17.5	87.7 ± 12.8

Medicine UPJŠ LF. The cause of death was not related to cardio-vascular diseases. In all the relevant cases, no histopathologically significant change in myocardium had been reported (n = 10). Autopsy protocols were registered in all ten cases between years 2014 to 2016. For example, one case was a 40-year-old woman that died by falling on the sidewalk with subsequent aspiration of gastric content. In another case, the death of a 45-year-old woman was caused by drowning during delusional deterioration. Another case was a still-born child, due to the asphyxiation of the umbilical cord. Other cases were two 28-year-old men who died after falling from a motorcycle. The tissue samples from the patients of the experimental group were collected during surgical remodeling of aorta or during the aortic valve replacement (AVR) surgery with a mechanical or biological prosthesis with or without replacement of the ascendant aorta. Other surgical interventions were mitral valve replacement (MVR) and off pump coronary revascularization (OPCAB). Surgery was done through median sternotomy with mild hypothermia using extracorporeal circulation. The cannulations were made in the ascendant aorta and in the right atrium of the heart, and the cold blood cardioplegia was also used. Cardioanesthesia was performed by standard operating procedures. The tissue taken from both groups was frozen in liquid nitrogen. Subsequently, all collected samples were stored in a freezer at temperature -71°C (New Brunswick Scientific, Enfield, CT, USA).

Isolation of RNA and RT-PCR

The commercial RNA isolation kit (RNeasy Mini Kit, Qiagen, Hilden, Germany) was used for RNA isolation from blood and tissue samples. The isolated RNA was transcribed into cDNA by using kit RevertAid H minus First strand

cDNA Synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA). The RT-PCR method was used to detect the changes in mRNA expression levels of the selected specific genes related to inflammation (hsCRP, IL6), and degradation of extracellular matrix (Emilin-1, MMP9, and TIMP). Amplification of the specific genes ran for 35 cycles (94°C 5 min, 95°C 10 s and 58-62°C 20 s and 72°C 25 s), using appropriate specific primer sequences (Table II) in the thermocycler Rotor Gene Q-PCR thermocycler (Qiagen, Hilden, Germany).

Normalization of the results was performed by using housekeeping genes Gapdh, HPRT, and ETNK. Numerical quantification of changes in the expression of mRNA levels was evaluated by the comparative quantification and Ct value Q Rotor Gene Software (Qiagen, Hilden, Germany). The difference between Δ Ct of the studied gene and the control gene was calculated, then, subtracted between Δ Ct of sample with unknown value and Δ Ct of the calibrator. The final result was a multiple of the calibrator value.

Protein Analysis by Randox Biochip

For the detection of the protein levels in the serum and tissue samples of both the experimental and control groups, a Cytokine Array IV assay kit was used in combination with a biochip analyzer (Evidence Investigator, Randox Laboratories Ltd., London, UK). The detection of proteins CRP, IL6, IL6R, hsCRP, MMP9, TNFR1, and TNFR2 started with the incubation of a sample with 200 μ l of assay buffer for 1 h/37°C/370 rpm of 100 μ l. After incubation, the procedure continued by decantation of the liquid and the washing of each well 2 times. The second incubation, using the same conditions, continued after adding conjugation buffer. After the second incubation, another decantation of liquid was done

Table II. List of used primer sequences.

Name of gene	Loci	Forward sequence	Reverse sequence	Length (bp)
IL6	Ex4	ACTTGCCCTGGTGAAAATCAT	TCTGGCTTGTTCCCTCACTACT	96
CRP	Ex1	AGCTCCCTATCTGGAGGATAGTT	CAAAGTCCATAACTCAATCCTTG	87
TIMP	Ex3	AAAGGCCGAGGGGGAC	AGCCCATCTGGTACCTGT	75
Emilin-1	Ex3	TACAAGACAGTGACCGACAT	AAGACGCAGGCCCA	97
MMP9	Ex9	TGAACCTGAGCCACGGC	GCTCTGAGGGGTGGACAGT	93
GAPDH	Ex1	TTTCTATAAATTGAGCCCGCA	ACCTGGCGACGCAAAA	87
HPRT	Ex6	TTGTTGGATTTGAAATTCCAG	ATTCAAATCCCTGAAGTATTCAT	87
ETNK	Ex1	TCTAGCCCTTAAATGCACAC	TGAATCTTACAGCAAACAG	182

and each well was washed 4 times. A mixture of luminol-EV-701 together with hydrogen peroxide was added to each well and incubated for 2 minutes. Visualization and calculation of the proteins levels (ng/ml) of each biomarker was performed using Evidence Investigation biochip software version 4 (Evidence Investigator, Randox Laboratories Ltd., London, UK).

Statistical Analysis

The categorical variables were analyzed using Pearson Chi-squared test, and continuous variables with normally distributed values were analyzed using a Student's *t*-test, whereas non-normally distributed continuous data were analyzed with a Mann-Whitney U-test for two independent samples and Kruskal-Wallis test for more than two independent samples. Statistical and Spearman correlation analysis was processed by the program GraphPad InSTAT (GraphPad, San Diego, CA, USA) and IBM SPSS Statistics 22.0 (IBM Corp., Armonk, NY, USA).

Results

Gene Expression Changes on mRNA Level

For determination of progressive valve inflammation and pathological remodeling of the valve

tissues during valve stenosis and regurgitation, the expression levels of specific genes (CRP, IL6, MMP9, Emilin-1, and TIMP) were detected from tissue using the RT-PCR method. Inflammatory marker CRP showed significantly increased values in both AS and AR in comparison with controls (about 284%, $p < 0.01$ and 372%, $p < 0.001$ higher) (Figure 1).

The expression of IL6 also showed significant differences in AS and AR against control (about 438%, $p < 0.001$ and 390%, $p < 0.01$ higher). Both genes, however, didn't show any significant difference suitable for specific recognition of AS from AR.

The differences between AS and AR were detected only in mRNA levels of MMP9 and TIMP, where increased levels characteristic for AS were found (about 74%, $p < 0.01$ and 87%, $p < 0.001$ higher than AR). An expression of Emilin-1 showed decreased levels in comparison with the control group in both AS and AR (about 123.7%, $p < 0.01$ and 73%, $p < 0.001$).

From the obtained results we can assume that MMP9/TIMP ratio is higher in the AS group (1.98, $p < 0.028$) in comparison with the AR group (1.60, $p < 0.05$) and, therefore, we suggest that an imbalance between MMP and TIMP expression is responsible for the shift toward a proteolytic state of ECM mostly in patients with AS.




Figure 1. Gene expression on mRNA levels in tissue. The mRNA levels of all detected genes were compared to controls (C, n = 10 autopsy samples). All data are presented as average \pm SD, ** $p < 0.01$, *** $p < 0.001$ means statistical significance against the control group. A red asterisk means significant difference between AS (n = 26) and AR (n = 32).

Molecular Changes on Protein Level

On protein levels, it was found in peripheral blood that from all the selected proteins only three (CRP, IL6, and IL2R) showed a significant difference between AS and AR. We detected very high levels of CRP in comparison with controls in both AR (about 44%, $p > 0.05$) and AS (about 236%, $p < 0.001$), which means that CRP levels in AS were about 133% ($p < 0.001$) higher than in AR (Figure 2).

Similar results were obtained by measurements of the protein IL6 from peripheral blood, where we found rising statistically significant increased levels in both AS and AR (about 129%, $p < 0.05$ and 57%, $p < 0.001$, respectively), which means about 47% ($p < 0.01$) higher levels in AS in comparison with AR. The protein levels of MMP9 didn't show any significant difference.

In the collected valve tissue of the experimental group, we found higher levels of protein receptors in AS and AR (IL6R, TNFR-1, and TNFR-2) in comparison with controls, but only one protein IL2R showed significant difference between AS and AR (AS had about 81% lower values than AR, $p < 0.01$) (Figure 3).

Pearson correlation in the group of patients with AR showed significant positive correlation between the serum IL6 and receptors TNFR1 and 2, as well as tissue mRNA of IL6 (Table III). The

group with AS, however, didn't show any significant correlation in the IL6 levels.

The mRNA levels were detected using tissue samples from patients with AS ($n = 26$) and AR ($n = 32$) collected during surgical intervention. Proteins levels were detected from blood serum of patients with AS ($n = 26$) and AR ($n = 32$) collected during surgical intervention.

Discussion

Aortic valve diseases are characterized by abnormalities of extracellular matrix, for which it is typical to find elastic fiber fragmentation, fibrosis, and calcification, resulting in aberrant angiogenesis, stenosis with or without regurgitation. Tissue remodeling of the extracellular matrix is a key pathophysiological feature of aortic stenosis. This process compromises valve integrity, augments the inflammatory response, and allows the expansion of calcified nodules¹⁶.

Inflammatory changes were proved by detection of mRNA and protein levels of hsCRP and IL6. In multivariate regression analysis, CRP emerged as an independent predictor of AS severity¹⁷. We found that hsCRP plasma levels of patients with AS were higher than both controls and patients with AR (mean 5.6 ng/ml),




Figure 2. Changes on protein level in the blood. The protein levels of all detected genes were compared to controls (C, $n = 35$). All data are presented as average \pm SD, $p < 0.05$, $**p < 0.01$, $***p < 0.001$ means statistical significance against the control group. A red asterisk means significant difference between AS ($n = 26$) and AR ($n = 32$).




Figure 3. Changes on protein levels in the blood. The protein levels of all detected genes were compared to controls (C, n = 35). All data are presented as average \pm SD, ** $p < 0.01$, *** $p < 0.001$ means statistical significance against the control group. A red asterisk means significant difference between AS (n = 26) and AR (n = 32).

which is supported by the results of Sharma et al¹⁸. They detected that plasmatic CRP concentration was significantly higher in patients with rapid AS progression (2.3 to 11.3 ng/ml). Protein IL6 also showed increased levels than control values in both groups AR and AS, specifically higher in patients with AS in comparison with AR group (about 47%). High production of IL-6 is related to an osteogenic transition and mineralization of the aortic valve¹⁹. IL-6 also promotes endothelial-mesenchymal transition in the aortic valve²⁰.

On the mRNA level, significant differences were also detected in the gene expression of markers of extracellular matrix remodeling, like Emilin-1, MMP9, and TIMP. Emilin-1 is localized at the interface between elastin and microfibrils in the artery and undoubtedly operates to facilitate the function of elastin, which plays an important role in arterial structure

and function²¹. Emilin-1 regulates elastogenesis and inhibits TGF- β signaling. There are several studies, which deal with the role of Emilin-1 in aortic tissue of patients with cardiovascular diseases. Munjal et al²¹ in their study identified Emilin-1 as extracellular matrix protein which is necessary for mature valve function and structure. Emilin-1 deficiency and the resulting elastic fiber assembly defects have been studied in the tissue of the aorta, showing that Emilin-1 deficiency causes TGF- β upregulation²². We found that Emilin-1 expression is non-significantly lower in AS group than AR group (about 29%, $p > 0.05$). However, the mRNA levels of MMP9 were significantly higher in the AS group in comparison with the AR group (about 74%, $p < 0.01$). Increased levels didn't correlate with protein levels. MMP-9 is involved in tissue remodeling through the degradation of extracellular matrix substrates like collagen and

Table III. Correlations of parameters in AR and AS with Pearson coefficients and p -values.

Marker	Aortic regurgitation			Aortic stenosis	
	IL6	TNFR2	IL6R	TNFR2	IL6R
TNFR1	0.592** 0.01	0.642** 0.01	0.937* 0.01	0.440* 0.05	
TNFR2	0.422* 0.025	0.424* 0.025			
mRNA IL6	0.438* 0.02				

elastin^{23,24}, but also involved in the conversion of cytokines and chemokines into active forms process proteins, like intercellular adhesion molecule-1 (ICAM-1)²⁵, and release proangiogenic factor VEGF-A^{26,27}. TIMP-1 is an endogenous inhibitor of MMP-9, whose low physiological level is disturbed under pathologic conditions, which results in excessive matrix degradation with subsequent vascular growth^{28,29}. The mRNA levels of TIMP were significantly elevated in AS group in comparison with AR group of patients (about 87%, $p < 0.001$), which suggests the increase of extracellular matrix degradation during AR. Interleukin receptors on protein levels showed the difference between AS and AR only in the levels of IL2 receptor, where we found about 81% lower values than AR ($p < 0.01$). Until now no data existed comparing the soluble protein of IL2R concentrations and the difference between AS and AR. Spearman correlation showed positive correlation between mRNA for IL6 in the valve tissue and its protein in blood of patients with AR ($p = 0.02$), which can help improve differential diagnostics. There may be some possible limitations in this study. The usage of health aortic valve tissue material (control group), that was taken from individuals during the autopsy in two to five hours after the traumatic death still showed relevant viability proved by the protein levels of CRP and IL6 that were found in range for healthy tissue samples. However, the small number of collected control samples suggests that our data should be interpreted with caution.

Conclusions

Cardiovascular diseases are one of the most common causes of death in the world. The study on the mechanism of formation of cardiovascular diseases presents motivation for application of new laboratory investigative methods. Finding new diagnostic biomarkers specific for aortic stenosis and regurgitation during early diagnosis can help not only in prevention but also during capture in the early stage of the disease and the subsequent successful treatment. This study described the differences in gene expression of inflammatory markers in blood and valve tissue on both mRNA and protein levels. We found that there are significant molecular changes specific for aortic stenosis that showed increased (IL6, CRP, MMP9, TIMP) or decreased (Emilin-1,

IL2R) expression levels than aortic regurgitation samples. The achieved results could contribute to the improvement of early diagnosis of selected cardiovascular disease in the future and improve the quality of patient's life.

Conflict of Interest

The Authors declare that they have no conflict of interests.

Acknowledgements

This work was supported by the Slovak Academy of Science and the Slovak Grant Agency for Science under the contracts VEGA 1/0873/16, Medipark II. ITMS 313011D103.

References

- 1) BENJAMIN EJ, VIRANI SS, CALLAWAY CW, CHAMBERLAIN AM, CHANG AR, CHENG S, CHIUVE SE, CUSHMAN M, DELLING FN, DEO R, DE FERRANTI SD, FERGUSON JF, FORNAGE M, GILLESPIE C, ISASI CR, JIMÉNEZ MC, JORDAN LC, JUDD SE, LACKLAND D, LICHTMAN JH, LISABETH L, LIU S, LONGENECKER CT, LUTSEY PL, MACKAY JS, MATCHAR DB, MATSUSHITA K, MUSSOLINO ME, NASIR K, O'FLAHERTY M, PALANIAPPAN LP, PANDEY A, PANDEY DK, REEVES MJ, RITCHEY MD, RODRIGUEZ CJ, ROTH GA, ROSAMOND WD, SAMPSON UKA, SATOU GM, SHAH SH, SPARTANO NL, TIRSCHWELL DL, TSAO CW, VOEKS JH, WILLEY JZ, WILKINS JT, WU JH, ALGER HM, WONG SS, MUNTNER P; AMERICAN HEART ASSOCIATION COUNCIL ON EPIDEMIOLOGY AND PREVENTION STATISTICS COMMITTEE AND STROKE STATISTICS SUBCOMMITTEE. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. *Circulation* 2018; 137: e67-e492.
- 2) DWECK MR, BOON NA, NEWBY DE. Calcific aortic stenosis: a disease of the valve and the myocardium. *J Am Coll Cardiol* 2012; 60: 1854-1863.
- 3) YARBROUGH WM, MUKHERJEE R, IKONOMIDIS JS, ZILE MR, SPINALE FG. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. *J Thorac Cardiovasc Surg* 2012; 143: 656-664.
- 4) NATARAJAN D, PRENDERGAST B. Aortic stenosis--pathogenesis, prediction of progression, and percutaneous intervention. *J R Coll Physicians Edinb* 2017; 47: 172-175.
- 5) STEINER I, KRBAL L, ROZKOS T, HARRER J, LACO J. Calcific aortic valve stenosis: Immunohistochemical analysis of inflammatory infiltrate. *Pathol Res Pract* 2012; 208: 231-234.
- 6) FANTUS D, AWAN Z, SEIDAH NG, GENEST J. Aortic calcification: novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor. *Atherosclerosis* 2013; 226: 9-15.

- 7) ANZAI T. Inflammatory mechanisms of cardiovascular remodeling. *Circ J* 2018; 82: 629-635.
- 8) DAHAL S, HUANG P, MURRAY BT, MAHLER GJ. Endothelial to mesenchymal transformation is induced by altered extracellular matrix in aortic valve endothelial cells. *J Biomed Mater Res A* 2017; 105: 2729-2741.
- 9) YU Z, SEYA K, DAITOKU K, MOTOMURA S, FUKUDA I, FURUKAWA K. Tumor necrosis factor- α accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway. *J Pharmacol Exp Ther* 2011; 337: 16-23.
- 10) OLSZOWSKA M. Pathogenesis and pathophysiology of aortic valve stenosis in adults. *Pol Arch Med Wewn* 2011; 121: 409-413.
- 11) LINDMAN BR, BONOW RO, OTTO CM. Current management of calcific aortic stenosis. *Circ Res* 2013; 113: 223-237.
- 12) WANG X, KHALIL RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. *Adv Pharmacol* 2018; 81: 241-330.
- 13) HAMIRANI YS, DIETL CA, VOYLES W, PERALTA M, BEGAY D, RAIZADA V. Acute aortic regurgitation. *Circulation* 2012; 126: 1121-1126.
- 14) NAKAMURA E, NAKAMURA K, NIINA K, KAZUSHI K, ISHII H, MD AI, KUBO H, SATORU I. Acute aortic regurgitation resulting from dehiscence of the aortic valve commissures. *Ann Thorac Cardiovasc Surg* 2010; 16: 294-296.
- 15) ISHII H, NAKAMURA K, NAGAHAMA H, MATSUYAMA M, ENDO G, NISHIMURA M. Two dehiscences of the aortic valve commissure and cusp with progressive acute aortic regurgitation. *Ann Vasc Dis* 2015; 8: 43-45.
- 16) CHANG RY, CHEN CC, HSU WP, HSIAO PC, TSAI HL, HSIAO PG, WU JD, GUO HR. Nontraumatic avulsion of aortic valve commissure as a cause of acute aortic valve regurgitation: a case report. *Medicine (Baltimore)* 2016; 95: e5053.
- 17) FERTIN M, DUBOIS E, BELLARD A, AMOUYEL P, PINET F, BAUTERS C. Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. *Am J Cardiol* 2012; 110: 277-283.
- 18) SHARMA G, SHETKAR S, BHASIN A, RAMAKRISHNAN L, JUNEJA R, NAIK N, ROY A, RAMAKRISHNAN S, BHARGAVA B, BAHL VK. High sensitive c-reactive protein and interleukin 6 in atrial fibrillation with rheumatic mitral stenosis from indian cohort. *Indian Heart J* 2017; 69: 505-511.
- 19) EL HUSSEINI D, BOULANGER MC, MAHMUT A, BOUCHAREB R, LAFLAMME MH, FOURNIER D, PIBAROT P, BOSSE Y, MATHIEU P. P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: Implication for calcific aortic valve disease. *J Mol Cell Cardiol* 2014; 72: 146-156.
- 20) MAHLER GJ, FARRAR EJ, BUTCHER JT. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. *Arterioscler Thromb Vasc Biol* 2013; 33: 121-130.
- 21) MUNJAL C, JEGGA AG, OPOKA AM, STOILOV I, NORRIS RA, THOMAS CJ, SMITH JM, MECHAM RP, BRESSAN GM, HINTON RB. Inhibition of MAPK-Erk pathway in vivo attenuates aortic valve disease processes in Emilin1-deficient mouse model. *Physiol Rep* 2017; 5: pii: e13152.
- 22) ZAVACKA M, FRANKOVICOVA M, POBEHOVA J, ZAVACKY P. The impact of the angioplasty of the renal artery and cold ischemia time in kidney transplantation on graft function. *Bratisl Lek Listy* 2018; 119: 416-420.
- 23) RANDELL A, DANESHTALAB N. Elastin microfibril interface-located protein 1, transforming growth factor beta, and implications on cardiovascular complications. *J Am Soc Hypertens* 2017; 11: 437-448.
- 24) KAPELOUZOU A, TSOURELIS L, KAKLAMANIS L, DEGIANNIS D, KOGERAKIS N, COKKINOS DV. Serum and tissue biomarkers in aortic stenosis. *Glob Cardiol Sci Pract* 2015; 2015: 49. doi: 10.5339/gcsp.2015.49. eCollection 2015.
- 25) CAUWE B, OPDENAKKER G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. *Crit Rev Biochem Mol Biol* 2010; 45: 351-423.
- 26) CHRISTOFFERSSON G, WALDEN T, SANDBERG M, OPDENAKKER G, CARLSSON PO, PHILLIPSON M. Matrix metalloproteinase-9 is essential for physiological beta cell function and islet vascularization in adult mice. *Am J Pathol* 2015; 185: 1094-1103.
- 27) WEI T, ZHANG H, CETIN N, MILLER E, MOAK T, SUEN JY, RICHTER GT. Elevated expression of matrix metalloproteinase-9 not matrix metalloproteinase-2 contributes to progression of extracranial arteriovenous malformation. *Sci Rep* 2016; 6: 24378.
- 28) HOU XD, DING F, WANG XK, LIU XG, YI K, ZHANG P, YOU T. Concomitant mitral valve replacement and tricuspid valvuloplasty for severe mitral stenosis. *Eur Rev Med Pharmacol Sci* 2017; 21: 3436-3440.
- 29) ALESSANDRI N, TUFANO F, PETRASSI M, ALESSANDRI C, DI CRISTOFANO C, DELLA ROCCA C, GALLO P. Atrial fibrillation in pure rheumatic mitral valvular disease is expression of an atrial histological change. *Eur Rev Med Pharmacol Sci* 2009; 13: 431-442.